Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

Stephen Mf Jamieson, Peter Tsai, Maria K. Kondratyev, Pratha Budhani, Arthur Liu, Neil N. Senzer, E. Gabriela Chiorean, Shadia Jalal, John J. Nemunaitis, Dennis Kee, Avik Shome, Way W. Wong, Dan Li, Nooriyah Poonawala-Lohani, Purvi M. Kakadia, Nicholas S. Knowlton, Courtney Rh Lynch, Cho R. Hong, Tet Woo Lee, Reidar A. GrénmanLaura Caporiccio, Trevor D. McKee, Mark Zaidi, Sehrish Butt, Andrew Mj Macann, Nicholas P. McIvor, John M. Chaplin, Kevin O. Hicks, Stefan K. Bohlander, Bradly G. Wouters, Charles P. Hart, Cristin G. Print, William R. Wilson, Michael A. Curran, Francis W. Hunter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number16
DOIs
StatePublished - Aug 23 2018

Fingerprint

Heterografts
Therapeutics
Biomarkers
Cell Line
Clustered Regularly Interspaced Short Palindromic Repeats
Carcinoma, squamous cell of head and neck
TH 302
Exome
RNA Sequence Analysis
Mechlorethamine
Prodrugs
Human Activities
Radiotherapy
Genome
DNA
Neoplasms
Tumor Hypoxia

Keywords

  • Cancer
  • Head & neck cancer
  • hypoxia
  • Oncology
  • Therapeutics

Cite this

Jamieson, S. M., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A., Senzer, N. N., ... Hunter, F. W. (2018). Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI insight, 3(16). https://doi.org/10.1172/jci.insight.122204

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. / Jamieson, Stephen Mf; Tsai, Peter; Kondratyev, Maria K.; Budhani, Pratha; Liu, Arthur; Senzer, Neil N.; Chiorean, E. Gabriela; Jalal, Shadia; Nemunaitis, John J.; Kee, Dennis; Shome, Avik; Wong, Way W.; Li, Dan; Poonawala-Lohani, Nooriyah; Kakadia, Purvi M.; Knowlton, Nicholas S.; Lynch, Courtney Rh; Hong, Cho R.; Lee, Tet Woo; Grénman, Reidar A.; Caporiccio, Laura; McKee, Trevor D.; Zaidi, Mark; Butt, Sehrish; Macann, Andrew Mj; McIvor, Nicholas P.; Chaplin, John M.; Hicks, Kevin O.; Bohlander, Stefan K.; Wouters, Bradly G.; Hart, Charles P.; Print, Cristin G.; Wilson, William R.; Curran, Michael A.; Hunter, Francis W.

In: JCI insight, Vol. 3, No. 16, 23.08.2018.

Research output: Contribution to journalArticle

Jamieson, SM, Tsai, P, Kondratyev, MK, Budhani, P, Liu, A, Senzer, NN, Chiorean, EG, Jalal, S, Nemunaitis, JJ, Kee, D, Shome, A, Wong, WW, Li, D, Poonawala-Lohani, N, Kakadia, PM, Knowlton, NS, Lynch, CR, Hong, CR, Lee, TW, Grénman, RA, Caporiccio, L, McKee, TD, Zaidi, M, Butt, S, Macann, AM, McIvor, NP, Chaplin, JM, Hicks, KO, Bohlander, SK, Wouters, BG, Hart, CP, Print, CG, Wilson, WR, Curran, MA & Hunter, FW 2018, 'Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma', JCI insight, vol. 3, no. 16. https://doi.org/10.1172/jci.insight.122204
Jamieson, Stephen Mf ; Tsai, Peter ; Kondratyev, Maria K. ; Budhani, Pratha ; Liu, Arthur ; Senzer, Neil N. ; Chiorean, E. Gabriela ; Jalal, Shadia ; Nemunaitis, John J. ; Kee, Dennis ; Shome, Avik ; Wong, Way W. ; Li, Dan ; Poonawala-Lohani, Nooriyah ; Kakadia, Purvi M. ; Knowlton, Nicholas S. ; Lynch, Courtney Rh ; Hong, Cho R. ; Lee, Tet Woo ; Grénman, Reidar A. ; Caporiccio, Laura ; McKee, Trevor D. ; Zaidi, Mark ; Butt, Sehrish ; Macann, Andrew Mj ; McIvor, Nicholas P. ; Chaplin, John M. ; Hicks, Kevin O. ; Bohlander, Stefan K. ; Wouters, Bradly G. ; Hart, Charles P. ; Print, Cristin G. ; Wilson, William R. ; Curran, Michael A. ; Hunter, Francis W. / Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. In: JCI insight. 2018 ; Vol. 3, No. 16.
@article{e5f606397f4a47af8ba4436564aebc5e,
title = "Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma",
abstract = "Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.",
keywords = "Cancer, Head & neck cancer, hypoxia, Oncology, Therapeutics",
author = "Jamieson, {Stephen Mf} and Peter Tsai and Kondratyev, {Maria K.} and Pratha Budhani and Arthur Liu and Senzer, {Neil N.} and Chiorean, {E. Gabriela} and Shadia Jalal and Nemunaitis, {John J.} and Dennis Kee and Avik Shome and Wong, {Way W.} and Dan Li and Nooriyah Poonawala-Lohani and Kakadia, {Purvi M.} and Knowlton, {Nicholas S.} and Lynch, {Courtney Rh} and Hong, {Cho R.} and Lee, {Tet Woo} and Gr{\'e}nman, {Reidar A.} and Laura Caporiccio and McKee, {Trevor D.} and Mark Zaidi and Sehrish Butt and Macann, {Andrew Mj} and McIvor, {Nicholas P.} and Chaplin, {John M.} and Hicks, {Kevin O.} and Bohlander, {Stefan K.} and Wouters, {Bradly G.} and Hart, {Charles P.} and Print, {Cristin G.} and Wilson, {William R.} and Curran, {Michael A.} and Hunter, {Francis W.}",
year = "2018",
month = "8",
day = "23",
doi = "10.1172/jci.insight.122204",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "16",

}

TY - JOUR

T1 - Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma

AU - Jamieson, Stephen Mf

AU - Tsai, Peter

AU - Kondratyev, Maria K.

AU - Budhani, Pratha

AU - Liu, Arthur

AU - Senzer, Neil N.

AU - Chiorean, E. Gabriela

AU - Jalal, Shadia

AU - Nemunaitis, John J.

AU - Kee, Dennis

AU - Shome, Avik

AU - Wong, Way W.

AU - Li, Dan

AU - Poonawala-Lohani, Nooriyah

AU - Kakadia, Purvi M.

AU - Knowlton, Nicholas S.

AU - Lynch, Courtney Rh

AU - Hong, Cho R.

AU - Lee, Tet Woo

AU - Grénman, Reidar A.

AU - Caporiccio, Laura

AU - McKee, Trevor D.

AU - Zaidi, Mark

AU - Butt, Sehrish

AU - Macann, Andrew Mj

AU - McIvor, Nicholas P.

AU - Chaplin, John M.

AU - Hicks, Kevin O.

AU - Bohlander, Stefan K.

AU - Wouters, Bradly G.

AU - Hart, Charles P.

AU - Print, Cristin G.

AU - Wilson, William R.

AU - Curran, Michael A.

AU - Hunter, Francis W.

PY - 2018/8/23

Y1 - 2018/8/23

N2 - Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.

AB - Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.

KW - Cancer

KW - Head & neck cancer

KW - hypoxia

KW - Oncology

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85062249490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062249490&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.122204

DO - 10.1172/jci.insight.122204

M3 - Article

C2 - 30135316

AN - SCOPUS:85062249490

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 16

ER -